These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 19183230

  • 1. Implications of insulin-like growth factor-I for prostate cancer therapies.
    Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y.
    Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
    [Abstract] [Full Text] [Related]

  • 2. Insulin-Like Growth Factor (IGF) family and prostate cancer.
    Gennigens C, Menetrier-Caux C, Droz JP.
    Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
    Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, Mayer D.
    Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
    [Abstract] [Full Text] [Related]

  • 11. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE.
    Mol Cell Endocrinol; 2011 Sep 15; 344(1-2):1-24. PubMed ID: 21782884
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor-I produced by seminal vesicles: relationship to intraepithelial basal cell hyperplasia in the prostate.
    Garcia FU, Urbanska K, Koltowski L, Reiss K, Sell C.
    Clin Cancer Res; 2007 Jun 01; 13(11):3140-6. PubMed ID: 17545516
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence?
    Meinbach DS, Lokeshwar BL.
    Urol Oncol; 2006 Jun 01; 24(4):294-306. PubMed ID: 16818181
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.
    Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M.
    Oncogene; 2005 Jul 07; 24(29):4736-40. PubMed ID: 15870705
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
    Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID.
    Urol Oncol; 2007 Jul 07; 25(2):134-40. PubMed ID: 17349528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.